StockNews.com Begins Coverage on Genocea Biosciences (NASDAQ:GNCA)
StockNews.com Begins Coverage on Genocea Biosciences (NASDAQ:GNCA)
Equities researchers at StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report released on Saturday. The firm set a "sell" rating on the biotechnology company's stock.
斯托克新聞網的股票研究人員在週六發佈的一份報告中開始報道Genocea Biosciences(納斯達克代碼：GNCA-GET Rating)的股票。該公司對這家生物技術公司的股票設定了“賣出”評級。
Genocea Biosciences Stock Performance
Genocea Bioscions股票表現
Shares of GNCA stock opened at $0.01 on Friday. The business's fifty day moving average price is $0.01 and its 200 day moving average price is $0.35. Genocea Biosciences has a 1-year low of $0.01 and a 1-year high of $2.16. The firm has a market capitalization of $657,820.80, a PE ratio of -0.02 and a beta of 1.96. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
上週五，GNCA的股票開盤報0.01美元。該業務的50日移動均線價格為0.01美元，其200日移動均線價格為0.35美元。Genocea Biosciences的一年低點為0.01美元，一年高位為2.16美元。該公司市值為657,820.80美元，本益比為-0.02，貝塔係數為1.96。該公司的債務權益比為0.24，流動比率為1.35，速動比率為1.35。
Institutional Inflows and Outflows
機構資金流入和流出
A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC acquired a new position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. 9.31% of the stock is owned by institutional investors and hedge funds.
一家對沖基金最近購買了Genocea Biosciences股票的新股份。根據Acadian Asset Management LLC在第四季度收購了Genocea Biosciences，Inc.(納斯達克代碼：GNCA-GET Rating)的新股票頭寸，該公司在最近提交給美國證券交易委員會的資訊中稱。該機構投資者購買了這家生物技術公司21,741股股票，價值約25,000美元。9.31%的股票由機構投資者和對沖基金持有。
About Genocea Biosciences
關於Genocea生物科學
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences，Inc.是一家生物製藥公司，發現和開發新型癌症免疫療法。該公司使用其專有的發現平臺ATLAS，該平臺描述了每個患者對下一代腫瘤測序確定的每個目標或抗原的CD4+和CD8+T細胞免疫反應。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免費獲取StockNews.com關於基因組生物科學的研究報告(GNCA)
- MarketBeat：回顧一週9/5-9/9
- 為網路安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦，這些股票可能表現優異
- DocuSign是否即將發生重大逆轉？
- 石油和天然氣股票：投資可再生能源的安全途徑
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Genocea Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。